Diabetic Therapeutic Drugs Industry Research Report 2025

Summary

According to APO Research, the global Diabetic Therapeutic Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Diabetic Therapeutic Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Diabetic Therapeutic Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Diabetic Therapeutic Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Diabetic Therapeutic Drugs include Arbutus Biopharma, AstraZeneca, Belrose Pharma, Dong-A ST, Eisai, F. Hoffmann-La Roche, Mitsubishi Tanabe Pharma, Novo Nordisk and Perle Biosciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Diabetic Therapeutic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetic Therapeutic Drugs.

The report will help the Diabetic Therapeutic Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Diabetic Therapeutic Drugs market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Diabetic Therapeutic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Diabetic Therapeutic Drugs Segment by Company

Arbutus Biopharma
AstraZeneca
Belrose Pharma
Dong-A ST
Eisai
F. Hoffmann-La Roche
Mitsubishi Tanabe Pharma
Novo Nordisk
Perle Biosciences
Sun Pharma
Pfizer
Eli Lilly
Merck
Novartis
Sanofi
Takeda Pharmaceuticals
Diabetic Therapeutic Drugs Segment by Type

Insulin Therapies
Non-Insulin Therapies
Diabetic Therapeutic Drugs Segment by Application

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Diabetic Therapeutic Drugs Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East Middle East & Africa
Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetic Therapeutic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diabetic Therapeutic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetic Therapeutic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Diabetic Therapeutic Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Diabetic Therapeutic Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Diabetic Therapeutic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Diabetic Therapeutic Drugs Market Size (2020-2031)
2.2.2 Global Diabetic Therapeutic Drugs Sales (2020-2031)
2.2.3 Global Diabetic Therapeutic Drugs Market Average Price (2020-2031)
2.3 Diabetic Therapeutic Drugs by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Insulin Therapies
2.3.3 Non-Insulin Therapies
2.4 Diabetic Therapeutic Drugs by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Type 1 Diabetes
2.4.3 Type 2 Diabetes
2.4.4 Gestational Diabetes
3 Market Competitive Landscape by Manufacturers
3.1 Global Diabetic Therapeutic Drugs Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Diabetic Therapeutic Drugs Sales (Tons) of Manufacturers (2020-2025)
3.3 Global Diabetic Therapeutic Drugs Revenue of Manufacturers (2020-2025)
3.4 Global Diabetic Therapeutic Drugs Average Price by Manufacturers (2020-2025)
3.5 Global Diabetic Therapeutic Drugs Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Diabetic Therapeutic Drugs, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Diabetic Therapeutic Drugs, Product Type & Application
3.8 Global Manufacturers of Diabetic Therapeutic Drugs, Established Date
3.9 Global Diabetic Therapeutic Drugs Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Arbutus Biopharma
4.1.1 Arbutus Biopharma Company Information
4.1.2 Arbutus Biopharma Business Overview
4.1.3 Arbutus Biopharma Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Arbutus Biopharma Diabetic Therapeutic Drugs Product Portfolio
4.1.5 Arbutus Biopharma Recent Developments
4.2 AstraZeneca
4.2.1 AstraZeneca Company Information
4.2.2 AstraZeneca Business Overview
4.2.3 AstraZeneca Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.2.4 AstraZeneca Diabetic Therapeutic Drugs Product Portfolio
4.2.5 AstraZeneca Recent Developments
4.3 Belrose Pharma
4.3.1 Belrose Pharma Company Information
4.3.2 Belrose Pharma Business Overview
4.3.3 Belrose Pharma Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Belrose Pharma Diabetic Therapeutic Drugs Product Portfolio
4.3.5 Belrose Pharma Recent Developments
4.4 Dong-A ST
4.4.1 Dong-A ST Company Information
4.4.2 Dong-A ST Business Overview
4.4.3 Dong-A ST Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Dong-A ST Diabetic Therapeutic Drugs Product Portfolio
4.4.5 Dong-A ST Recent Developments
4.5 Eisai
4.5.1 Eisai Company Information
4.5.2 Eisai Business Overview
4.5.3 Eisai Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Eisai Diabetic Therapeutic Drugs Product Portfolio
4.5.5 Eisai Recent Developments
4.6 F. Hoffmann-La Roche
4.6.1 F. Hoffmann-La Roche Company Information
4.6.2 F. Hoffmann-La Roche Business Overview
4.6.3 F. Hoffmann-La Roche Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.6.4 F. Hoffmann-La Roche Diabetic Therapeutic Drugs Product Portfolio
4.6.5 F. Hoffmann-La Roche Recent Developments
4.7 Mitsubishi Tanabe Pharma
4.7.1 Mitsubishi Tanabe Pharma Company Information
4.7.2 Mitsubishi Tanabe Pharma Business Overview
4.7.3 Mitsubishi Tanabe Pharma Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Mitsubishi Tanabe Pharma Diabetic Therapeutic Drugs Product Portfolio
4.7.5 Mitsubishi Tanabe Pharma Recent Developments
4.8 Novo Nordisk
4.8.1 Novo Nordisk Company Information
4.8.2 Novo Nordisk Business Overview
4.8.3 Novo Nordisk Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Novo Nordisk Diabetic Therapeutic Drugs Product Portfolio
4.8.5 Novo Nordisk Recent Developments
4.9 Perle Biosciences
4.9.1 Perle Biosciences Company Information
4.9.2 Perle Biosciences Business Overview
4.9.3 Perle Biosciences Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Perle Biosciences Diabetic Therapeutic Drugs Product Portfolio
4.9.5 Perle Biosciences Recent Developments
4.10 Sun Pharma
4.10.1 Sun Pharma Company Information
4.10.2 Sun Pharma Business Overview
4.10.3 Sun Pharma Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Sun Pharma Diabetic Therapeutic Drugs Product Portfolio
4.10.5 Sun Pharma Recent Developments
4.11 Pfizer
4.11.1 Pfizer Company Information
4.11.2 Pfizer Business Overview
4.11.3 Pfizer Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Pfizer Diabetic Therapeutic Drugs Product Portfolio
4.11.5 Pfizer Recent Developments
4.12 Eli Lilly
4.12.1 Eli Lilly Company Information
4.12.2 Eli Lilly Business Overview
4.12.3 Eli Lilly Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Eli Lilly Diabetic Therapeutic Drugs Product Portfolio
4.12.5 Eli Lilly Recent Developments
4.13 Merck
4.13.1 Merck Company Information
4.13.2 Merck Business Overview
4.13.3 Merck Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Merck Diabetic Therapeutic Drugs Product Portfolio
4.13.5 Merck Recent Developments
4.14 Novartis
4.14.1 Novartis Company Information
4.14.2 Novartis Business Overview
4.14.3 Novartis Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.14.4 Novartis Diabetic Therapeutic Drugs Product Portfolio
4.14.5 Novartis Recent Developments
4.15 Sanofi
4.15.1 Sanofi Company Information
4.15.2 Sanofi Business Overview
4.15.3 Sanofi Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.15.4 Sanofi Diabetic Therapeutic Drugs Product Portfolio
4.15.5 Sanofi Recent Developments
4.16 Takeda Pharmaceuticals
4.16.1 Takeda Pharmaceuticals Company Information
4.16.2 Takeda Pharmaceuticals Business Overview
4.16.3 Takeda Pharmaceuticals Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2020-2025)
4.16.4 Takeda Pharmaceuticals Diabetic Therapeutic Drugs Product Portfolio
4.16.5 Takeda Pharmaceuticals Recent Developments
5 Global Diabetic Therapeutic Drugs Market Scenario by Region
5.1 Global Diabetic Therapeutic Drugs Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Diabetic Therapeutic Drugs Sales by Region: 2020-2031
5.2.1 Global Diabetic Therapeutic Drugs Sales by Region: 2020-2025
5.2.2 Global Diabetic Therapeutic Drugs Sales by Region: 2026-2031
5.3 Global Diabetic Therapeutic Drugs Revenue by Region: 2020-2031
5.3.1 Global Diabetic Therapeutic Drugs Revenue by Region: 2020-2025
5.3.2 Global Diabetic Therapeutic Drugs Revenue by Region: 2026-2031
5.4 North America Diabetic Therapeutic Drugs Market Facts & Figures by Country
5.4.1 North America Diabetic Therapeutic Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Diabetic Therapeutic Drugs Sales by Country (2020-2031)
5.4.3 North America Diabetic Therapeutic Drugs Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Diabetic Therapeutic Drugs Market Facts & Figures by Country
5.5.1 Europe Diabetic Therapeutic Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Diabetic Therapeutic Drugs Sales by Country (2020-2031)
5.5.3 Europe Diabetic Therapeutic Drugs Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Diabetic Therapeutic Drugs Market Facts & Figures by Country
5.6.1 Asia Pacific Diabetic Therapeutic Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Diabetic Therapeutic Drugs Sales by Country (2020-2031)
5.6.3 Asia Pacific Diabetic Therapeutic Drugs Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Diabetic Therapeutic Drugs Market Facts & Figures by Country
5.7.1 South America Diabetic Therapeutic Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Diabetic Therapeutic Drugs Sales by Country (2020-2031)
5.7.3 South America Diabetic Therapeutic Drugs Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa Diabetic Therapeutic Drugs Market Facts & Figures by Country
5.8.1 Middle East and Africa Diabetic Therapeutic Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Diabetic Therapeutic Drugs Sales by Country (2020-2031)
5.8.3 Middle East and Africa Diabetic Therapeutic Drugs Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Diabetic Therapeutic Drugs Sales by Type (2020-2031)
6.1.1 Global Diabetic Therapeutic Drugs Sales by Type (2020-2031) & (Tons)
6.1.2 Global Diabetic Therapeutic Drugs Sales Market Share by Type (2020-2031)
6.2 Global Diabetic Therapeutic Drugs Revenue by Type (2020-2031)
6.2.1 Global Diabetic Therapeutic Drugs Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Diabetic Therapeutic Drugs Revenue Market Share by Type (2020-2031)
6.3 Global Diabetic Therapeutic Drugs Price by Type (2020-2031)
7 Segment by Application
7.1 Global Diabetic Therapeutic Drugs Sales by Application (2020-2031)
7.1.1 Global Diabetic Therapeutic Drugs Sales by Application (2020-2031) & (Tons)
7.1.2 Global Diabetic Therapeutic Drugs Sales Market Share by Application (2020-2031)
7.2 Global Diabetic Therapeutic Drugs Revenue by Application (2020-2031)
7.2.1 Global Diabetic Therapeutic Drugs Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Diabetic Therapeutic Drugs Revenue Market Share by Application (2020-2031)
7.3 Global Diabetic Therapeutic Drugs Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Diabetic Therapeutic Drugs Value Chain Analysis
8.1.1 Diabetic Therapeutic Drugs Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Diabetic Therapeutic Drugs Production Mode & Process
8.2 Diabetic Therapeutic Drugs Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Diabetic Therapeutic Drugs Distributors
8.2.3 Diabetic Therapeutic Drugs Customers
9 Global Diabetic Therapeutic Drugs Analyzing Market Dynamics
9.1 Diabetic Therapeutic Drugs Industry Trends
9.2 Diabetic Therapeutic Drugs Industry Drivers
9.3 Diabetic Therapeutic Drugs Industry Opportunities and Challenges
9.4 Diabetic Therapeutic Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings